Value-Added Medicines

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Adalvo and CNX Therapeutics have launched the first extended-release formulation of a pregabalin generic in the UK.

Amneal has spoken excitedly about its Crexont (carbidopa/levodopa) extended-release capsules as the Parkinson’s disease drug passes six months on the market.

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

Reformulation specialist Lipella has an eye on numerous milestones for its proposed oral rinse liposomal formulation of tacrolimus, including the submission of a Phase IIb clinical trial investigational new drug application.